Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Pediatric Neurology · DNAJC6-Related Juvenile Parkinsonism (PARK19A)

The Science of PARK19A and Your Child's Diagnosis

At a Glance

PARK19A is a DNAJC6-related form of juvenile parkinsonism. Reduced auxilin activity can disrupt the recycling of message-carrying bubbles in brain cells, so children may have movement problems together with developmental delays, seizures, cognitive changes, or swallowing difficulties.

To understand PARK19A, it helps to look deep inside the brain cells (neurons) at how they communicate. Most genetic conditions that cause parkinsonism in children affect how the cell creates energy or cleans up waste. PARK19A is different because it breaks the “recycling system” that allows brain cells to send messages efficiently [1][2].

The Biology: Recycling the “Messenger Bubbles”

Brain cells talk to each other by releasing chemical messengers stored in tiny bubbles called synaptic vesicles. Once a bubble releases its message, the cell must quickly “recycle” it so it can be refilled and used again.

  1. The Clathrin Coat: To pull a new bubble back into the cell, a protein called clathrin forms a protective “coat” or cage around it [1].
  2. The Role of Auxilin: This is where the DNAJC6 gene comes in. It provides instructions for a protein called auxilin. Think of auxilin as the “unzipper.” It attaches to the clathrin cage and signals another protein to strip the coat off [1][3].
  3. The Breakdown: In PARK19A, the cell doesn’t have enough working auxilin. In simplified research models, the clathrin coats stay stuck on the bubbles, preventing them from being recycled. The precise mechanisms of neuronal dysfunction and degeneration remain under study, but it is believed that over time communication breaks down [4][5].

“Pure” vs. “Complex” Parkinsonism

Doctors often use overlapping clinical patterns to categorize movement disorders. Understanding the difference helps explain why PARK19A can look different from typical Parkinson’s disease.

  • Primary Motor Parkinsonism: This refers to conditions that primarily cause movement issues (tremors, stiffness, slowness). Genes like PRKN (Parkin), PINK1, and PARK7 often fall into this category, though they can also include non-motor features. Children with these forms often respond well to standard medications [6][7][8].
  • Complex (Atypical) Parkinsonism: PARK19A often presents as “complex” because it frequently involves “extra” symptoms like developmental delays, seizures, and cognitive changes that aren’t usually seen in the primary motor forms [5][9].

How Doctors Tell the Difference

Because many rare conditions look similar at first, doctors perform a differential diagnosis—a process of elimination to ensure they have the right answer.

Condition Primary Gene Key Distinguishing Features
PARK19A DNAJC6 Often starts with developmental delay or “losing” skills; may include seizures and swallowing issues [5][9].
PRKN/PINK1 PRKN, PINK1 Usually starts later; often predominantly motor; response to medication can be very high [7][8].
PARK14 PLA2G6 Often involves eye movement problems and “pyramidal signs” (unusual reflexes or weakness) [10][11].
Kufor-Rakeb ATP13A2 May include unique eye movement issues and significant cognitive or psychiatric features [12][13].

Knowing that PARK19A is the specific cause allows your medical team to focus on the specific challenges—like seizures or developmental support—that come with this particular “recycling” problem [5].

Common questions in this guide

What is PARK19A, and which gene causes it?
PARK19A is a genetic form of juvenile parkinsonism associated with changes in the DNAJC6 gene. DNAJC6 provides instructions for auxilin, a protein that helps brain cells recycle the small vesicles used to send chemical messages.
How can a DNAJC6 change affect communication between brain cells?
Auxilin helps remove the clathrin coat from a message-carrying vesicle after it releases its signal, so the vesicle can be reused. When working auxilin is reduced, this recycling process may be impaired and brain-cell communication may become less efficient. The exact steps leading to nerve-cell dysfunction are still being studied.
What symptoms may a child with PARK19A develop?
PARK19A may cause movement problems along with developmental delay or loss of previously acquired skills, seizures, cognitive changes, and swallowing difficulties. The combination and severity of symptoms can differ from one child to another.
Why do doctors compare PARK19A with other forms of juvenile parkinsonism?
Several rare genetic conditions can look similar at first, so doctors use a differential diagnosis to compare the age of onset, movement symptoms, developmental history, seizures, eye movements, and other features. This comparison helps distinguish PARK19A from conditions such as PRKN- or PINK1-related parkinsonism, PARK14, and Kufor-Rakeb syndrome.
How can identifying PARK19A help guide my child's care?
Knowing that DNAJC6-related PARK19A is the underlying cause helps the medical team anticipate features that may need attention, including seizures, developmental needs, cognitive changes, and swallowing problems. It also helps clinicians tailor discussions and support to the child's specific pattern rather than focusing only on movement symptoms.

Get notified when new evidence is published on Juvenile onset Parkinson disease 19A.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease.

    Gorenberg EL, Chandra SS

    Frontiers in neuroscience 2017; (11()):248 doi:10.3389/fnins.2017.00248.

    PMID: 28579939
  2. 2

    Impaired pre-synaptic plasticity and visual responses in auxilin-knockout mice.

    Cheng X, Tang Y, Vidyadhara DJ, et al.

    iScience 2023; (26(10)):107842 doi:10.1016/j.isci.2023.107842.

    PMID: 37766983
  3. 3

    Reconstitution of Clathrin Coat Disassembly for Fluorescence Microscopy and Single-Molecule Analysis.

    Böcking T, Upadhyayula S, Rapoport I, et al.

    Methods in molecular biology (Clifton, N.J.) 2018; (1847()):121-146 doi:10.1007/978-1-4939-8719-1_10.

    PMID: 30129014
  4. 4

    Neurodevelopmental and synaptic defects in DNAJC6 parkinsonism, amenable to gene therapy.

    Abela L, Gianfrancesco L, Tagliatti E, et al.

    Brain : a journal of neurology 2024; (147(6)):2023-2037 doi:10.1093/brain/awae020.

    PMID: 38242634
  5. 5

    DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism-Dystonia.

    Ng J, Cortès-Saladelafont E, Abela L, et al.

    Movement disorders : official journal of the Movement Disorder Society 2020; (35(8)):1357-1368 doi:10.1002/mds.28063.

    PMID: 32472658
  6. 6

    Clinical Variability of SYNJ1-Associated Early-Onset Parkinsonism.

    Lesage S, Mangone G, Tesson C, et al.

    Frontiers in neurology 2021; (12()):648457 doi:10.3389/fneur.2021.648457.

    PMID: 33841314
  7. 7

    Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review.

    Kasten M, Hartmann C, Hampf J, et al.

    Movement disorders : official journal of the Movement Disorder Society 2018; (33(5)):730-741 doi:10.1002/mds.27352.

    PMID: 29644727
  8. 8

    Rethinking 'rare' PINK1 Parkinson's disease: A meta-analysis of geographical prevalence, phenotypic diversity, and α-synuclein pathology.

    Yin EP, Dieriks BV

    Journal of Parkinson's disease 2025; (15(1)):41-65 doi:10.1177/1877718X241304814.

    PMID: 39973502
  9. 9

    Novel Homozygous Pathogenic Variant in DNAJC6 Causes Rapid Progressive Parkinsonism.

    Pessoa ALS, Guimarães TG, de Castro Dos Santos D, et al.

    Movement disorders clinical practice 2026; doi:10.1002/mdc3.70731.

    PMID: 42414182
  10. 10

    Clinical Profile and Genetic Composition of Patients With Juvenile Parkinsonism From a Single Tertiary Care Center in India.

    Farsana MK, Holla VV, Phulpagar P, et al.

    Journal of movement disorders 2026; (19(1)):19-30 doi:10.14802/jmd.25132.

    PMID: 40829774
  11. 11

    Case Report: Where is the boundary between autosomal recessive early-onset Parkinson's disease and dystonia-parkinsonism: a case of PLA2G6-associated neurodegeneration.

    Li XT, Yuan CX, Lv ZQ, et al.

    Frontiers in human neuroscience 2026; (20()):1772073 doi:10.3389/fnhum.2026.1772073.

    PMID: 42158583
  12. 12

    ATP13A2 novel mutations causing a rare form of juvenile-onset Parkinson disease.

    Suleiman J, Hamwi N, El-Hattab AW

    Brain & development 2018; (40(9)):824-826 doi:10.1016/j.braindev.2018.05.017.

    PMID: 29903538
  13. 13

    Successful treatment of psychosis in a patient with Kufor-Rakeb syndrome with low dose aripiprazole: a case report.

    McNeil-Gauthier AL, Brais B, Rouleau G, et al.

    Neurocase 2019; (25(3-4)):133-137 doi:10.1080/13554794.2019.1625928.

    PMID: 31232173

This page is for informational purposes only and does not constitute medical advice. Your child's pediatric neurologist and genetics team should interpret DNAJC6 or PARK19A findings and symptoms in context.